

Risks priced in, valuation support emerges

Cipla reported a weak 3QFY26 with revenue/EBITDA/PAT coming in at flat/-37%/-57% YoY, materially below expectations, with EBITDA margins contracting to 17.7% (-1,038bps YoY) driven by lower gRevlmid contribution, adverse product mix and elevated R&D spend. North America (-22% YoY) remained the key drag, impacted by sharper-than-expected gRevlmid decline and temporary halt in Lanreotide supplies, though the base business sustained double digit momentum. India delivered steady growth (+10% YoY) led by strong traction across all sub-segments. Other markets were stable, with Emerging Markets and Europe growing 13% YoY, while One Africa saw modest growth amid channel destocking. The US weakness on account of gRevlmid decline was a known factor, but the recent supply side issues in Lanreotide and increased R&D intensity has led to downward revision of our estimates. However, the stock has corrected ~21% from recent highs, largely on expectations of a weaker quarterly performance. With better visibility on post-Revlmid margin normalization, Lanreotide supply constraints, and a seasonally weak quarter already well flagged, we believe most of the near-term risks are now priced in, limiting the scope for further downgrades. At current levels, the stock trades at ~21x (-2SD) on FY28E EPS, a ~12% discount to its historical average multiple of 24x, offering an attractive entry point to start building positions amid weak broader market sentiment. Thus, we value the stock at 23x FY28E EPS, marginally lower than historical average, to arrive at a TP of INR 1,431. Upgrade to ADD.

- Strong headwinds surround North America (INR 14.8bn | -22% YoY):** The quarter was particularly muted for the segment with CC sales of USD 167mn (vs -25% YoY), driven by decreasing contribution from gRevlmid, though the weakness was more than earlier anticipated. Another reason for a weak 3Q was halt in Lanreotide in November due to FDA observation at partner's facility, however, Cipla is expecting supply to begin again in 1HFY27 with further plans to on-board an alternate partner down the line. The silver lining for the quarter is double-digit YoY growth in the base business excluding gRevlmid, even post factoring Lanreotide in 3QFY25 base.
- US pipeline provides some relief in-sight:** Cipla currently has 4 respiratory (incl. gAdvair) and 4 peptides (incl. gliraglutide) in pipeline. Of the 4 respiratory, 2 unnamed products are likely to be large opportunities with Cipla as the sole player, and one of these two can potentially be a top 5 product for Cipla. Further, the 4 respiratory products are in-house, with 3 out of these 4 filed from on-shore facilities, thus ensuring higher margins. Timeline wise, over next 6 months, Cipla anticipates launch of 1 major respiratory asset, 1 small respiratory asset, gAdvair, gliraglutide and another small peptide. A large respiratory asset along with a major peptide opportunity is to follow in the subsequent 6 months. Though, the earlier guidance of FY27 US sales of 1bn seems dicey due to Lanreotide issues, the pipeline visibility provides cushion to the gRevlmid decline.
- India sustains momentum (INR 34.5bn | +10% YoY):** The growth was led by all the three sub-segments – Branded prescriptions, Trade generics and Consumer healthcare. In Branded prescriptions, double-digit growth was driven by outperformance in key therapies, namely – respiratory (+11% YoY), urology (+15% YoY), cardiac (+13% YoY), and anti-diabetes (+13% YoY). In 3Q, Cipla added 4 brands to INR 1b+ club, taking the total to 30. On the portfolio expansion front, Cipla entered into an exclusive agreement with Pfizer for select products, acquired Inzpera to extend differentiated paediatric & wellness portfolio, launched AfreZZA and entered in a marketing partnership with Eli Lilly for Tirzepatide. Trade Generics' healthy growth was led by distribution, new introductions and technological interventions. In 3Q, Cipla launched 8 new products, including the coverage expansion via sexual wellness product. Going forward, the focus is on execution to outperform the market and strengthen presence in chronic therapies.

Amey Chalke

amey.chalke@jmfl.com | Tel: (91 22) 66303056

Abin Benny

abin.benny@jmfl.com | Tel: (91 22) 69703621

We acknowledge the support of **Gourav Bhama** (gourav.bhama@jmfl.com) in preparation of this report

Recommendation and Price Target

Current Reco.	ADD
Previous Reco.	REDUCE
Current Price Target (12M)	1,431
Upside/(Downside)	8.8%
Previous Price Target	1,600
Change	-10.6%

Key Data – CIPLA IN

Current Market Price	INR1,315
Market cap (bn)	INR1,062.2/US\$11.6
Free Float	70%
Shares in issue (mn)	807.0
Diluted share (mn)	807.0
3-mon avg daily val (mn)	INR2,401.5/US\$26.1
52-week range	1,673/1,303
Sensex/Nifty	81,538/25,049
INR/US\$	92.0

Price Performance

%	1M	6M	12M
Absolute	-12.4	-10.8	-9.2
Relative*	-8.1	-9.5	-14.8

* To the BSE Sensex

Financial Summary						(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E	
Net Sales	2,57,741	2,75,476	2,84,276	3,08,739	3,37,674	
Sales Growth (%)	13.3	6.9	3.2	8.6	9.4	
EBITDA	62,911	71,279	60,025	63,494	70,583	
EBITDA Margin (%)	24.4	25.9	21.1	20.6	20.9	
Adjusted Net Profit	32,009	39,578	39,217	45,312	50,213	
Diluted EPS (INR)	39.7	49.0	48.6	56.1	62.2	
Diluted EPS Growth (%)	22.0	23.6	-0.9	15.5	10.8	
ROIC (%)	21.8	25.1	18.2	18.2	19.1	
ROE (%)	12.8	13.7	11.9	12.3	12.2	
P/E (x)	33.2	26.8	27.1	23.4	21.1	
P/B (x)	4.0	3.4	3.0	2.7	2.4	
EV/EBITDA (x)	16.1	13.8	15.9	14.6	12.7	
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	

Source: Company data, JM Financial. Note: Valuations as of 23/Jan/2026

JM Financial Research is also available on:
 Bloomberg - JMFR <GO>, FactSet, LSEG and
 S&P Capital IQ.

Please see Appendix I at the end of this report
 for Important Disclosures and Disclaimers and
 Research Analyst Certification.

- Other markets:** The One Africa segment grew 3% YoY to come in at INR 10bn, aided by market outperformance in the South Africa's secondary private market. The company faced weakness in primary sales due to the in-country channel destocking. However, normalization is expected in 4Q. Focus going forward is on improving the private sector mix while being selective in tenders. In Emerging Markets and Europe, the company delivered a healthy 13% YoY growth with INR 9.2bn topline, while sustaining overall margins. The performance was led by both DTM and B2B categories. Future strategy entails top-line growth via deepening penetration in core markets and parallelly maintaining strong margin trajectory.
- Our view and valuation:** The weakness in North America business on account of gRevlmid decline was a known factor, but the recent supply side issues in Lanreotide and increased R&D intensity has led to downward revision of our estimates (exhibit 2). The stock has corrected ~21% from recent highs, largely on expectations of a weaker quarterly performance. With better visibility on post-Revlmid margin normalization, Lanreotide supply constraints, and a seasonally weak quarter already well flagged, we believe most of the near-term risks are now priced in, limiting the scope for further downgrades. At current levels, the stock trades at ~21x (-2 SD) on FY28E EPS, a ~12% discount to its historical average multiple of 24x, offering an attractive entry point to start building positions amid the weak broader market sentiment. Thus, we value the stock at 23x FY28E EPS, marginally lower than the historical average, to arrive at a TP of INR 1,431. Upgrade to ADD.


- Financial highlights:**

- Revenue at INR 70.7bn (Flat YoY | -6%/-6% vs street/JMFe)
- Gross profit of INR 44.4bn (-8% YoY | -11% vs JMFe). Gross margin at 63% (-519bps YoY | -356bps vs JMFe); GM was impacted by both lower gRevlmid as well as product mix.
- EBITDA at INR 12.5bn (-37% YoY | -28%/-30% VS street/JMFe)
- EBITDA margin at 17.7% (-1038bps YoY | -553bps/-607bps vs street/JMFe); Decline in EBITDA margins was due to lower gRevlmid contribution. R&D was higher than usual too in the quarter at 7% vs 5-5.5% in the past, owing to heavy pipeline. R&D guidance going forward is at 5-6% of sales.
- EBITDA margin guidance for FY26 reduced to 21%.
- PAT at INR 6.8bn (-57% YoY | -46%/-50% vs street/JMFe)

Segmental Analysis

- USA -22% YoY (-17% vs JMFe)
- Domestic +10% YoY (In-line with JMFe)
- South Africa+2% YoY (-7% vs JMFe)
- Intl mkts +11% YoY (-3% vs JMFe)
- APIs +14% YoY (-18% vs JMFe)

Exhibit 1. Stock trading at attractive valuations



Source: Bloomberg

Exhibit 2. Change in estimates

INR mn	FY26E			FY27E			FY28E		
	Old	New	change %	Old	New	change %	Old	New	change %
Net sales	2,90,462	2,84,276	-2%	3,10,767	3,08,739	-1%	3,36,587	3,37,674	0%
Gross profit	1,94,900	1,86,201	-4%	1,98,891	1,97,593	-1%	2,14,406	2,15,098	0%
- margin	67.2%	65.5%	-170bps	64.0%	64.0%	0bps	63.7%	63.7%	0bps
EBITDA	69,639	60,025	-13.8%	68,066	63,494	-7%	75,012	70,583	-6%
- margin	25.1%	21.1%	-397bps	21.9%	20.6%	-130bps	22.3%	20.9%	-138bps
Net profit	48,668	43,201	-11.2%	46,924	45,312	-3%	52,375	50,213	-4%

Source: JM Financial

Exhibit 3. Valuation methodology

Particulars	INR
FY28 EPS	62.2
Multiple (x)	23
TP	1431
CMP	1,315
Upside	+8.8%

Source: JM Financial

Exhibit 4. 3QFY26 review

Cipla P&L (INR mn)	Q3 FY25	Q3 FY26	% YoY	Q3 FY26	% Delta vs JMFe	Q2FY26E (cons)	% Delta vs cons	Q2 FY26	% QoQ
<i>(in INR mn)</i>									
Net Sales	69,616	69,630	0%	74,407	-6%			74,474	-7%
Other op. income	1,114	1,115	0%	800	39%			1,420	-21%
Total operating income	70,730	70,745	0%	75,207	-6%	75,279	-6%	75,894	-7%
Expenses									
Raw material	22,641	26,321	16%	25,300	4%			24,976	5%
Gross Profit	48,089	44,424	-8%	49,907	-11%			50,918	
% Margins	68.0%	62.8%	-519 bps	66.4%	-356 bps			67.1%	
Staff cost	11,976	13,250	11%	13,100	1%			13,148	1%
Other operating expenses	16,224	18,624	15%	18,900	-1%			18,823	-1%
EBITDA	19,889	12,551	-37%	17,907	-30%	17,517	-28%	18,948	-34%
% EBITDA Margin	28.1%	17.7%	-1038 bps	23.8%	-607 bps	23.3%	-553 bps	25.0%	-722 bps
Other income	2,216	2,063	-7%	2,700	-24%			2,690	-23%
Finance costs	146	140	-4%	140	0%			132	6%
Depreciation	2,798	2,784	-1%	3,087	-10%			2,970	-6%
Profit Before Tax (PBT)	19,161	11,690	-39%	17,379	-33%			18,535	-37%
Exceptional Items	0	-2,759		0				0	
Tax	3,324	2,186	-34%	4,000	-45%			5,005	-56%
% Tax rate	17.3%	18.7%		23.0%				27.0%	
Minority interest	-41	16		77				-22	
Share of Profit (+) / Loss (-) of associates	-91	-3		5				3	
Reported PAT	15,705	6,758	-57%	13,461	-50%	12,470	-46%	13,512	-50%

% Cost Ratios	Q3 FY25	Q3 FY26	% YoY	Q3 FY26	% Delta vs JMFe	Q2 FY26	% QoQ
Raw Materials	32.0	37.2	519 bps	33.6	356 bps	32.9	430 bps
Staff cost	16.9	18.7	180 bps	17.4	131 bps	17.3	140 bps
Mfg & Other expense	22.9	26.3	339 bps	25.1	119 bps	24.8	152 bps

Sales Break-up	Q3 FY25	Q3 FY26	% YoY	Q3 FY26	% Delta vs JMFe	Q2 FY26	% QoQ
Domestic formulations	31,460	34,570	10%	34,449	0%	31,460	10%
US	19,060	14,850	-22%	17,835	-17%	20,390	-27%
South Africa	7,690	7,840	2%	8,459	-7%	9,010	-13%
International Markets	10,300	11,460	11%	11,794	-3%	12,440	-8%
APIs	1,260	1,440	14%	1,750	-18%	1,480	-3%

Source: Company, JM Financial

Financial Tables (Consolidated)

Income Statement						(INR mn)				
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E					
Net Sales	2,57,741	2,75,476	2,84,276	3,08,739	3,37,674					
Sales Growth	13.3%	6.9%	3.2%	8.6%	9.4%					
Other Operating Income	0	0	0	0	0					
Total Revenue	2,57,741	2,75,476	2,84,276	3,08,739	3,37,674					
Cost of Goods Sold/Op. Exp	88,196	89,290	98,075	1,11,146	1,22,576					
Personnel Cost	43,100	48,328	52,591	57,117	62,470					
Other Expenses	63,534	66,579	73,585	76,982	82,046					
EBITDA	62,911	71,279	60,025	63,494	70,583					
EBITDA Margin	24.4%	25.9%	21.1%	20.6%	20.9%					
EBITDA Growth	25.1%	13.3%	-15.8%	5.8%	11.2%					
Depn. & Amort.	10,510	11,070	11,111	12,227	13,393					
EBIT	52,401	60,210	48,913	51,267	57,190					
Other Income	7,466	8,619	9,500	10,000	10,500					
Finance Cost	899	620	600	650	550					
PBT before Excep. & Forex	58,968	68,208	57,813	60,617	67,140					
Excep. & Forex Inc./Loss(-)	-1,948	0	0	0	0					
PBT	57,020	68,208	57,813	60,617	67,140					
Taxes	15,466	15,298	14,453	15,154	16,785					
Extraordinary Inc./Loss(-)	0	0	0	0	0					
Assoc. Profit/Min. Int.(-)	306	-252	-239	-247	-256					
Reported Net Profit	41,216	52,725	43,201	45,312	50,213					
Adjusted Net Profit	32,009	39,578	39,217	45,312	50,213					
Net Margin	12.4%	14.4%	13.8%	14.7%	14.9%					
Diluted Share Cap. (mn)	807.0	807.0	807.0	807.0	807.0					
Diluted EPS (INR)	39.7	49.0	48.6	56.1	62.2					
Diluted EPS Growth	22.0%	23.6%	-0.9%	15.5%	10.8%					
Total Dividend + Tax	0	0	0	0	0					
Dividend Per Share (INR)	0.0	0.0	0.0	0.0	0.0					

Source: Company, JM Financial

Balance Sheet						(INR mn)				
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E					
Shareholders' Fund	2,67,064	3,11,935	3,49,466	3,89,113	4,33,661					
Share Capital	1,615	1,615	1,611	1,611	1,611					
Reserves & Surplus	2,65,450	3,10,319	3,47,855	3,87,501	4,32,050					
Preference Share Capital	0	0	0	0	0					
Minority Interest	959	958	958	958	958					
Total Loans	5,594	4,382	3,882	3,382	2,882					
Def. Tax Liab. / Assets (-)	-4,025	-5,913	-5,913	-5,913	-5,913					
Total - Equity & Liab.	2,69,592	3,11,361	3,48,393	3,87,539	4,31,588					
Net Fixed Assets	1,06,464	1,14,615	1,21,438	1,25,211	1,31,819					
Gross Fixed Assets	1,17,156	1,31,674	1,51,674	1,71,674	1,91,674					
Intangible Assets	47,130	49,864	49,864	49,864	49,864					
Less: Depn. & Amort.	66,465	79,050	90,162	102,389	115,781					
Capital WIP	8,643	12,128	10,062	6,062	6,063					
Investments	40,659	39,712	39,712	39,712	39,712					
Current Assets	1,74,178	2,13,096	2,53,167	2,95,415	3,39,024					
Inventories	52,380	56,421	70,614	80,025	88,254					
Sundry Debtors	47,707	55,064	52,307	56,808	62,132					
Cash & Bank Balances	56,820	80,931	1,09,199	1,37,040	1,66,459					
Loans & Advances	2	156	174	193	214					
Other Current Assets	17,270	20,524	20,873	21,349	21,965					
Current Liab. & Prov.	51,708	56,061	65,923	72,798	78,967					
Current Liabilities	26,037	29,966	31,995	36,047	39,590					
Provisions & Others	25,671	26,094	33,928	36,751	39,377					
Net Current Assets	1,22,470	1,57,035	1,87,244	2,22,617	2,60,057					
Total - Assets	2,69,593	3,11,362	3,48,393	3,87,540	4,31,588					

Source: Company, JM Financial

Dupont Analysis					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Margin	12.4%	14.4%	13.8%	14.7%	14.9%
Asset Turnover (x)	0.9	0.9	0.8	0.8	0.8
Leverage Factor (x)	1.1	1.1	1.1	1.1	1.1
RoE	12.8%	13.7%	11.9%	12.3%	12.2%
Key Ratios					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
BV/Share (INR)	330.9	386.5	433.0	482.2	537.4
ROIC	21.8%	25.1%	18.2%	18.2%	19.1%
ROE	12.8%	13.7%	11.9%	12.3%	12.2%
Net Debt/Equity (x)	-0.2	-0.2	-0.3	-0.3	-0.4
P/E (x)	33.2	26.8	27.1	23.4	21.1
P/B (x)	4.0	3.4	3.0	2.7	2.4
EV/EBITDA (x)	16.1	13.8	15.9	14.6	12.7
EV/Sales (x)	3.9	3.6	3.4	3.0	2.7
Debtor days	68	73	67	67	67
Inventory days	74	75	91	95	95
Creditor days	46	51	49	51	52

Source: Company, JM Financial

Source: Company, JM Financial

History of Recommendation and Target Price

Date	Recommendation	Target Price	% Chg.
30-Jul-22	Hold	975	
4-Nov-22	Hold	1,020	4.6
26-Jan-23	Hold	1,030	1.0
28-Feb-23	Hold	930	-9.7
13-May-23	Hold	950	2.2
26-Jul-23	Hold	990	4.2
29-Oct-23	Hold	1,155	16.7
25-Jan-24	Hold	1,275	10.4
12-May-24	Hold	1,360	6.7
28-Jul-24	Hold	1,460	7.4
4-Sep-24	Hold	1,515	3.8
29-Oct-24	Hold	1,537	1.5
28-Jan-25	Hold	1,570	2.1
13-May-25	Hold	1,619	3.1
25-Jul-25	Hold	1,544	-4.6
31-Oct-25	Reduce	1,600	3.6

Recommendation History



APPENDIX I

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Rating System: Definition of ratings	
Rating	Meaning
BUY	Expected return $\geq 15\%$ over the next twelve months.
ADD	Expected return $\geq 5\%$ and $< 15\%$ over the next twelve months.
REDUCE	Expected return $\geq -10\%$ and $< 5\%$ over the next twelve months.
SELL	Expected return $< -10\%$ over the next twelve months.

Note: For REITs (Real Estate Investment Trust) and InvIT (Infrastructure Investment Trust) total expected returns include dividends or DPU (distribution per unit)

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions. Please click [here](#) to access our detailed Terms and Conditions, including the Most Important Terms and Conditions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1177 Avenue of the Americas, 5th Floor, Offices 5045 and 5046, New York, New York 10036. Telephone +1 (332) 900 4956 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: ashley.johnson@jmfl.com

Grievance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: instcompliance@jmfl.com